Lunai Bioworks Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Lunai Bioworks
Pharmaceutical Preparations, SIC 2834
Lunai Bioworks Inc. is an artificial intelligence-driven biotechnology company that focuses on precision medicine, biomarker discovery, and therapy development for central nervous system disorders, biodefense, and severe diseases with unmet needs. The company functions primarily through two operating segments: Renovaro Biosciences and BioSymetrics. Renovaro Biosciences develops allogeneic cell and gene therapy candidates, focusing on genetically modified dendritic cell therapeutic vaccines targeting solid tumors like pancreatic and triple-negative breast cancers. BioSymetrics operates a biomedical artificial intelligence platform that combines multimodal biological data, proprietary machine learning models, and phenotypic knowledge graphs with experimental validation. The company collaborates with pharmaceutical enterprises, academic organizations, and healthcare providers to develop research programs and analytical discovery tools.
The organization maintains business operations and active corporate subsidiaries situated across the United States, the Netherlands, Denmark, Canada, and the United Kingdom. Lunai Bioworks is headquartered in Sacramento, California.
Summary of the business section of Lunai Bioworks's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lunai Bioworks Inc.
- Headquarters
- Suite 906 Los Angeles, CA
- Address
- Century City Medical Plaza, 2080 Century City East 90067
- Phone
- (453) 917-9840
- Employees
- 12, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- Sadler, Gibb & Associates, LLC, Draper, UT
Stock & identifiers
- Ticker
- LNAI
- Exchange
- Nasdaq
- Shares outstanding
- 36M, May 15, 2026
- Public float
- $111.90M, Dec 31, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-8 reverse, May 22, 2026; 1-for-10 reverse, Nov 14, 2025; 1-for-10 reverse, Sep 30, 2025
- SEC CIK
- 1527728
- CUSIP
- 29350E302
- ISIN
- US29350E3027
- LEI
- 5493003O12Q6PNJ56V39
- EIN
- 45-2259340
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Hershel Weinstein | Chief Executive Officer, Director | 250,000 |
| Nathen Fuentes | Chief Financial Officer | – |
| Simon Tarsh | Interim CFO | – |
| Tilburg Maurice van | Director | 250,000 |
| Mark Anthony Collins | Director | – |
| Douglas W. Calder | Director | – |
| James A. McNulty | Director | – |
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had 12 full-time employees.”
Corporate history
Events identified from SEC filings